Skip to content
Descubridor Institucional UMAR
Inicio
Búsqueda avanzada
Explorar
Inicio
Búsqueda avanzada
Explorar
Login
Language
English
Deutsch
Español
Français
Italiano
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
What are the risks of combined sitagliptin and dapagliflozin in type 2 diabetes patients?
What are the risks of combined sitagliptin and dapagliflozin in type 2 diabetes patients?
Fuente:
Zenodo
Saved in:
Bibliographic Details
Main Author:
Tripdatabase
Format:
Recurso digital
Published:
Zenodo
2025
Subjects:
risks
combined
sitagliptin
dapagliflozin
type
diabetes
patients
Online Access:
Acceder al recurso
Tags:
Add Tag
No Tags, Be the first to tag this record!
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Holdings
Description
Comments
Similar Items
Staff View
Internet
https://doi.org/10.5281/zenodo.17705620
Similar Items
Should dapagliflozin be discontinued before a surgical procedure?
by: Tripdatabase
Published: (2025)
Figure 1 from: Habeeb MQ, Abdulridha MK, Salman IN (2026) Metabolic effects of mangosteen supplementation as an adjuvant to sitagliptin/metformin in newly diagnosed type 2 diabetes Iraqi patients. Pharmacia 73: 1-9. https://doi.org/10.3897/pharmacia.73.e182949
by: Habeeb, Mays Qays, et al.
Published: (2026)
How effective are educational interventions by diabetic specialist nurses in improving patients' understanding of diabetes management?
by: Tripdatabase
Published: (2026)
What are the risks of combining cannabis with stimulant medication for ADHD?
by: Tripdatabase
Published: (2025)
EVALUATION OF THE EFFICACY OF SGLT2 INHIBITOR THERAPY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
by: Cotoneț, Tatiana, et al.
Published: (2025)